Study Summary:
Multicenter, randomized, double-blind, placebo-controlled, parallel-group two year study to evaluate the effect of Subcutaneous ro4909832 on cognition and function in Prodromal Alzheimer's disease.
Qualified Participants Must:
• Be between 50 and 85 years of age
•
Have a study partner to provide information as to the subjects cognitive and functional abilities
•
Not be currently taking medication for the treatment of AD
MMSE of 24 or above
Qualified Participants May Receive:
Subcutaneous injection of Study Medication every 4 weeks for 2 years.
Compensation for time and travel
Study related assessments